This is a phase I trial of the EPCAM protein in conjunction with liposomal adjuvant administered to patients with metastatic EPCAM-expressing GI tumors. To date, the protein administered with the liposomal adjuvant has been well tolerated with no toxicity. Immune response is pending.
Showing the most recent 10 out of 570 publications